MedTrace Logo

Artificial Tears Study in Mild to Moderate Dry Eye Patients

NCT00607776 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-02-03

No results posted yet for this study

Summary

The mean change in the subjective comfort score from baseline of the test group is at least 2.0 units less than that of the control group.

Conditions

  • Dry Eye

Interventions

DRUG

(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400

Drops

DRUG

Systane

Drops

Sponsors & Collaborators

  • Abbott Medical Optics

    lead INDUSTRY

Principal Investigators

  • Eric Donnenfeld, M.D. · Ophthalmic Consultants of Long Island

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Completion
2007-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00607776 on ClinicalTrials.gov